Latest news with #INSPIRAART100
Yahoo
15-04-2025
- Business
- Yahoo
Inspira Technologies Announces Successful Treatment of First Patient with INSPIRA ART100 at Westchester Medical Center
First Clinical Use of INSPIRA ART100 System Successfully Completes Full Treatment Cycle, Validating the Technology's Performance in a Real-World Clinical Environment and Garnering Overwhelmingly Positive Feedback RA'ANANA, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the successful completion of the first human treatment using its U.S. Food and Drug Administration-cleared INSPIRA™ ART100 system in a critical life-support procedure. The procedure was successfully performed by expert physicians at Westchester Medical Center in New York State, marking the first real-world implementation of Inspira's innovative technology. During the life-support procedure, the INSPIRA ART100 effectively provided comprehensive heart and lung support by oxygenating and circulating the patient's blood. Following the procedure, the patient was safely transitioned off the system, demonstrating its effective support. Dr. David Spielvogel, MD, Section Chief of Cardiothoracic Surgery at Westchester Medical Center commented: "The INSPIRA ART100 system performed exceptionally well during this critical procedure. We were particularly impressed with the system's reliability and responsiveness throughout the procedure. I believe that the seamless transition during both the connection and disconnection phases demonstrated the technology's sophistication and clinical readiness. This successful first case represents a promising advancement in extracorporeal support technology that could benefit numerous patients requiring this level of care. We look forward to continuing and expanding our relationship with Inspira." Joe Hayon, President of Inspira, added: "This first successful patient use of INSPIRA ART100 is a pivotal milestone for Inspira, validating the real-world potential of the INSPIRA ART100. We believe that the positive outcome at Westchester Medical Center sets the stage for broader adoption across leading hospitals, with Glo-Med Networks Inc. ('Glo-Med'), our U.S. distributor. We remain committed to expanding clinical use and advancing critical care solutions for patients worldwide." The installation, training program and professional services relating to the clinical use of the INSPIRA ART100 was led by Inspira Technologies Inspira Technologies is developing innovative respiratory support and diagnostics technologies. The Company's flagship INSPIRA ART500 system also known as the INSPIRA ART aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in both the U.S. and for Cardiopulmonary Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company's HYLA™ blood sensor technology is designed to provide continuous, real-time blood monitoring without the need for blood draws. The Company's pipeline products, including the INSPIRA ART500, and HYLA blood sensor, are currently in development and have not yet received regulatory approval. For more information, please visit our corporate website at About Glo-Med Networks, Inc. Glo-Med, known for delivering unique healthcare solutions, collaborates with top medical device and biomedical companies worldwide to meet the growing demand for innovative medical devices and related products in domestic and international markets. Glo-Med maintains extensive access to next-generation medical products globally via long-term partnerships and relationships with medical providers and through its sister company focused on medical device servicing with a focus on hospital beds and medical mattresses, Med-Stat Consulting Services, Inc. (est. 2003). Along with the largest and most prominent healthcare organizations in New York and Florida as clients, Glo-Med has offices and partner companies in the U.S., Latin America, Europe, the Middle East, and Africa, providing extensive access to the global medical network. For more information, please visit the corporate website: Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that the INSPIRA ART100 represents a promising advancement in extracorporeal support technology that could benefit numerous patients, the prospective future collaboration between Westchester Medical Center and Inspira, the belief that the seamless transition during both the connection and disconnection phases of the patient treatment demonstrated the technology's sophistication and clinical readiness, the belief that the successful patient treatment with the INSPIRA ART100 represents a huge milestone for the Company and validates its technology's potential to transform critical care, the belief that the positive outcome at Westchester Medical Center sets the stage for broader adoption across leading hospitals, led by Glo-Med, and the belief that the successful deployment of its system in a leading cardiopulmonary facility demonstrates the readiness of its technology for real-world clinical applications. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at ContactInspira Technologies – Media Relations Email: info@ Phone: +972-9-9664485 Capital Markets & Investor ContactArx | Capital Markets Advisors North American Equities Desk inspira@
Yahoo
19-03-2025
- Business
- Yahoo
Inspira Technologies' Innovative Life-Support System to be Showcased at AmSECT 63rd International Conference 2025 in San Diego
Leading perfusion professionals to experience Inspira's FDA-cleared cardiopulmonary bypass INSPIRA™ ART100 technology at premier industry event RA'ANANA, Israel, March 19, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira," "Inspira Technologies" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that its U.S. Food and Drug Administration-cleared life-support system, the INSPIRA™ ART100, will be showcased at the American Society of Extracorporeal Technology (AmSECT) 63rd International Conference, taking place March 19-23, 2025, at the Loews Coronado Bay Resort in San Diego, California, by their distributor Glo-Med Networks Inc ("Glo-Med"). Conference attendees will have the opportunity to explore Inspira's cutting-edge cardiopulmonary bypass technology at Glo-Med's booth. The INSPIRA ART100 system, which received FDA 510(k) clearance in May 2024 for use in cardiopulmonary bypass procedures, represents an advancement in extracorporeal circulation technology. "The AmSECT International Conference brings together leading perfusion professionals, providing an ideal platform to showcase our INSPIRA ART100 system," said Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies. "This event offers an excellent opportunity to further expose our innovative technology to the perfusion community. We look forward to connecting with industry experts and demonstrating how our solutions can support medical professionals." Visitors interested in scheduling a personal meeting are welcome to contact Mr. Levi Perryman at levi@ or visit Booth number 4. About AmSECT 63rd International Conference The American Society of ExtraCorporeal Technology (AmSECT) International Conference is the premier global event for perfusion professionals, focusing on advancements in extracorporeal circulation, patient care, and perfusion education. The event will feature the latest medical technologies, research, and discussions shaping the future of perfusion. About Inspira Technologies Inspira Technologies is developing innovative respiratory support and diagnostics technologies. The Company's flagship INSPIRA ART500 system aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in the U.S. and for Cardiopulmonary Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company's HYLA blood sensor technology is designed to provide continuous, real-time blood monitoring without the need for blood draws. The Company's pipeline products, including the INSPIRA ART500 (Gen 2), INSPIRA Cardi-ART, and HYLA blood sensor, are currently in development and have not yet received regulatory approval. For more information, visit: Company ContactInspira Technologies – Media RelationsEmail: info@ +972-9-9664485 Capital Markets & Investor ContactArx | Capital Markets AdvisorsNorth American Equities Deskinspira@ View original content: SOURCE Inspira Technologies Sign in to access your portfolio
Yahoo
11-03-2025
- Business
- Yahoo
Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates
Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by significant technological advancements and a major regulatory milestone. We successfully obtained 510(k) clearance from the Food and Drug Administration ("FDA") for our INSPIRA™ ART100 system and began its preparation for deployment in leading hospitals in the United States. In 2025, our focus is on the rapid advancement of our flagship INSPIRA™ ART core technologies, with the HYLA™ blood monitoring sensor expected to lead the way towards our planned FDA submission for clearance in the second half of the year. We've already deployed the FDA-cleared INSPIRA ART100 system to Westchester Memorial Center, NY, for its evaluation by their team of medical experts using the device in clinical procedures pursuant to the collaboration with the hospital." Recent Business and Operational Highlights FDA-Cleared System Deployment: In January 2025, Inspira delivered its FDA-cleared INSPIRA ART100 systems to Glo-Med Networks Inc. for distribution to hospitals across the east coast of the U.S., including, as reported, a cardiothoracic surgery division at a leading New York hospital ranked among the top 15 percent of cardiothoracic programs in the U.S. The deployment includes collaborative support from both parties to ensure seamless integration of this unique technology into clinical use. VORTX™ Technology Advancement: In January 2025, the Company unveiled a modular configuration for its VORTX blood oxygenation technology, representing a significant advancement in extracorporeal oxygenation with the potential to transform critical care practices by reducing harmful effects on blood components. HYLA™ Blood Sensor Clinical Results: In March 2025, Inspira announced positive results from the clinical study of its AI-powered HYLA™ blood sensor, which achieved 96% accuracy for a key parameter compared to traditional blood test analyzers. Additionally, a new indicator for identifying oxygen deficiencies demonstrated 92.3% accuracy. The clinical study, conducted at Sheba Medical Center, involved six patients undergoing open-heart surgery with the clip-on HYLA blood sensor monitoring blood parameters in real-time. The Company plans to advance with the ongoing clinical study and expects FDA submission for the first HYLA configuration in the second half of 2025. Manufacturing Partnership: In January 2025, the Company established a dedicated production line for a crucial flow mechanism component to be integrated into Inspira's products for use in the extracorporeal circulation of blood during the oxygenation process. The collaboration with Zriha Medical Ltd., a leading international manufacturer specializing in medical device production, enables to support scaling of production for its innovative respiratory support system and candidate technologies. INSPIRA ART100 System Enhancements: In January 2025, Inspira introduced new support features for the INSPIRA ART100 system designed to assist medical teams, reduce staff overhead, and improve efficiency through customizable protocols and advanced alarm troubleshooting capabilities. Infection Prevention Technology: In February 2025, Inspira reported positive initial results from its collaboration with Ennocure MedTech Ltd., with ex-vivo testing showing a 95% reduction in bacterial presence within 4 hours using a novel bio-electronic patch technology designed to prevent bloodstream infections. Leadership Strengthening: In January 2025, the Company appointed Mr. Tal Parnes as the new Chairman of the Board, bringing over three decades of experience in the medical technology and pharmaceutical sectors to enhance the Company's strategic vision and market positioning. In January 2025, the Company accepted Prof. Goldwasser's resignation from his position, which was due to personal reasons. Increasing Operational Efficiency: In 2024, Inspira implemented strategic cost management while maintaining focused research and development (R&D) investments and achieving significant technological advancements. The Company strategically managed R&D expenses by optimizing personnel resources, and securing government grants, all without compromising progress toward critical product milestones. Full Year 2024 Financial Highlights Operating Expenses: Total operating expenses decreased to US$11,267,000 in the year ended December 31, 2024, from US$12,133,000 in the same period in 2023. R&D Investments: R&D expenses decreased to US$6,323,000 for the year ended December 31, 2024, from US$7,320,000 in the same period in 2023. The decrease was primarily attributable to the reflection of the exchange rate on salary and related expenses, changes in the Company's staffing and development project's needs, and an Israel Innovation Authority grant deducted from the R&D expenses. G&A Expenses: General and administrative (G&A) expenses increased to US$4,185,000 for the year ended December 31, 2024, from US$4,063,000 in the same period in 2023. The increase was primarily attributable to an increase in professional fees, salary and related expenses and share-based compensation. Sales and Marketing: Sales and marketing (S&M) expenses increased to US$754,000 for the year ended December 31, 2024, from US$746,000 in the same period in 2023. The increase is attributable to an increase in salary and related expenses and share-based compensation that is offset by decrease in professional fees paid for projects related to digital marketing and media materials. Net Loss: Net loss attributable to ordinary shareholders was US$11,053,000 in 2024, compared with US$11,286,000 in 2023. Cash Position: As of December 31, 2024, the Company had cash, cash equivalents and deposits of US$5,779,000 compared to US$7,361,000 as of December 31, 2023, providing financial stability to support ongoing product development and upcoming regulatory submissions. Financial Liabilities: As of December 31, 2024, financial liabilities at fair value totaled US$1,575,000 compared to US$1,470,000. The financial liabilities represent the fair value of the Company's equity liabilities. About Inspira Technologies Inspira Technologies is developing innovative respiratory support and diagnostics technologies. The Company's flagship INSPIRA ART system aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in the U.S. and for Cardiopulmonary Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company's HYLA blood sensor technology is designed to provide continuous, real-time blood monitoring without the need for blood draws. The Company's pipeline products, including the INSPIRA ART (Gen 2), INSPIRA Cardi-ART, and HYLA blood sensor, are currently in development and have not yet received regulatory approval. For more information, visit: Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential benefits of its products, the expected timing of its FDA submissions, the expected results and impact of its clinical studies, the deployment of its product, and its belief that its reduced total expenses, its strategic investments in R&D and its cash position provide it with a solid foundation to support its ongoing product development initiatives and upcoming regulatory submissions in 2025. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at STATEMENTS OF BALANCE SHEETS(US dollars in thousands)December 31,December 31,20242023 ASSETSCurrent Assets:Cash and cash equivalents 5,1115,041 Cash deposits 6682,320 Other accounts receivable 587432 Inventory 444- Total current assets 6,8107,793 Non-Current Assets:Right of use assets, net 7611,011 Property, plant and equipment, net 499506 Total non-current assets 1,2601,517 Total Assets 8,0709,310December 31,December 31,20242023 LIABILITIES AND SHAREHOLDERS' EQUITYCurrent Liabilities:Trade accounts payables 154198 Other accounts payable 1,3641,026 Lease liabilities 277290 Financial Liabilities at Fair Value 1,5751,470 Total current liabilities 3,3702,984 Non-Current Liabilities:Lease liabilities 378588 Total non- current liabilities 378588 Shareholders' Equity:Share capital and additional paid in capital 70,89661,259 Accumulated deficit (66,574)(55,521) Total equity 4,3225,738 Total Liabilities and Shareholders' Equity 8,0709,310 STATEMENTS OF COMPREHENSIVE LOSS(US dollars in thousands)Year endedDecember 31, 2024Year endedDecember 31, 2023 Research and development expenses 6,3237,320 General and administrative expenses 4,1854,063 Sales and marketing expenses 754746 Other expenses (income) 54 Operating loss 11,26712,133 Interest Income from deposits (172)(318) Finance expenses(income), net (42)(529) Loss before tax 11,05311,286 Taxes on income -- Total comprehensive loss for the period 11,05311,286 STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(US dollars in thousands) For the year Ended December 31, 2024: Number of shares Share capital and additional paid in capital Accumulated deficit TotalBalance on January 01, 2024 15,652,17661,259 (55,521)5,738Changes during the period:Issuance of ordinary shares, private warrants and Pre-funded warrants, net 6,231,1697,679 -7,679Exercise of options 19,0482 -2Exercise of June 2024 Pre-funded warrants into ordinary shares 1,709,7602 -2Restricted share unit ("RSU") vesting 594,943- --Issuance of ordinary Shares- advisor fees 45,00062 -62Share-based compensation -1,892 -1,892Comprehensive and net loss -- (11,053)(11,053)Balance on December 31, 2024 24,252,09670,896 (66,574)4,322For More Financial Information: For a comprehensive understanding of the Company's financial reports and related management's discussion and analysis for applicable periods, please review the company's annual report on Form 20-F for the fiscal year ended December 31, 2024, available on the company's EDGAR profile at Company Contact Inspira Technologies – Media RelationsEmail: info@ +972-9-9664485 Capital Markets & Investor Contact Arx | Capital Markets AdvisorsNorth American Equities Deskinspira@ Logo: View original content: SOURCE Inspira Technologies Sign in to access your portfolio
Yahoo
05-03-2025
- Business
- Yahoo
PESG Report: Inspira Technologies Breaks new Ground with Positive Clinical Data for AI-Powered Blood Sensor Exceeding Expectations
Inspira Technologies* reports groundbreaking clinical results for its AI-powered HYLA blood sensor, achieving 96% accuracy in a key parameter and 92.3% accuracy in detecting oxygen deficiencies. These impressive findings provide new validation the company's innovative non-invasive monitoring technology and strengthen its position in both the $5.7 billion blood gas analyzer market and the $19 billion mechanical ventilation market. With FDA submission on track for H2 2025 and the INSPIRA ART100 system already being deployed to U.S. hospitals, the company continues to build momentum in its multi-pronged strategy to revolutionize critical care. NEW YORK, March 05, 2025--(BUSINESS WIRE)--PESG Research releases an update following groundbreaking clinical evaluation results: Inspira Technologies* (NASDAQ: IINN) has reported exceptional clinical study outcomes for its HYLA blood sensor, with 96% accuracy achieved in a key parameter compared to traditional blood analyzers. This milestone achievement validates the company's AI-powered continuous blood monitoring technology and accelerates its path toward commercial deployment in multiple healthcare settings. Promising Clinical Validation at Premier Medical Institution The clinical study, conducted at Sheba Hospital (ranked among the world's top 8 hospitals by Newsweek), successfully demonstrated the HYLA sensor's capabilities across 6 patients undergoing open-heart surgery. The clip-on device monitored blood parameters in real-time as blood circulated through the cardiopulmonary bypass system, achieving impressive concordance with conventional laboratory testing methods. Notably, the study also validated a new indicator for identifying oxygen deficiencies, showing 92.3% accuracy – a critical capability for preventing hypoxia during surgical procedures. This clinical validation at one of the world's premier medical institutions represents a significant de-risking event for the company's core technology. As Dagi Ben-Noon, CEO of Inspira, noted, "Achieving 96% accuracy as reflected in our clinical results in real-time blood monitoring without the need for blood draws represents a significant technological breakthrough." Expanding Technology Ecosystem Shows Commercial Progress The successful HYLA clinical results come amid accelerating commercial momentum for Inspira's broader product ecosystem. The company's INSPIRA ART100 system, which received FDA 510(k) clearance in May 2024 for cardiopulmonary bypass procedures, is now being deployed at leading U.S. hospitals through distribution partner Glo-Med Networks. The system was recently enhanced with new support features designed to assist medical teams, reduce staff overhead, and improve efficiency during critical procedures. Additionally, in February 2025, Inspira reported positive initial results from its collaboration with Ennocure MedTech Ltd. to develop a novel bio-electronic treatment for preventing bloodstream infections. Ex-vivo testing demonstrated a 95% reduction in bacterial presence within 4 hours, showing promise for addressing the estimated 250,000 bloodstream infections related to intravenous lines occurring worldwide annually. Inspira's Strategy Targets Multiple High-Value Markets The successful clinical validation of the HYLA blood sensor represents a crucial step in Inspira's strategy to penetrate multiple high-value medical technology markets. As a standalone technology, HYLA targets the blood gas analyzer market, which the company projects will reach $5.7 billion by 2030 (up from previous estimates of $2.5 billion). When integrated with Inspira's respiratory support systems, the technology strengthens the company's position in the $19 billion mechanical ventilation market. Inspira's approach of combining AI-enhanced monitoring capabilities with innovative respiratory support solutions addresses a critical unmet need in healthcare. With approximately 20 million patients annually requiring mechanical ventilation globally and mortality rates exceeding 50% under current protocols, Inspira's technology ecosystem offers a potential paradigm shift in critical care management by enabling conscious patient treatment with continuous monitoring. Click here to Subscribe for more updates like this Latest News from Inspira: Inspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving 96% Accuracy Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections Inspira Technologies Integrates New Oxygenation Indicator into AI-Powered HYLA Blood Sensor * Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by PESG Research, a brand affiliated with the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by Inspira prior to publication. Please review the full disclaimers and compensation disclosures here: View source version on Contacts PESG Editorial Desk ronald@
Associated Press
05-03-2025
- Business
- Associated Press
PESG Report: Inspira Technologies Breaks new Ground with Positive Clinical Data for AI-Powered Blood Sensor Exceeding Expectations
PESG Research releases an update following groundbreaking clinical evaluation results: Inspira Technologies* (NASDAQ: IINN) has reported exceptional clinical study outcomes for its HYLA blood sensor, with 96% accuracy achieved in a key parameter compared to traditional blood analyzers. This milestone achievement validates the company's AI-powered continuous blood monitoring technology and accelerates its path toward commercial deployment in multiple healthcare settings. Promising Clinical Validation at Premier Medical Institution The clinical study, conducted at Sheba Hospital (ranked among the world's top 8 hospitals by Newsweek), successfully demonstrated the HYLA sensor's capabilities across 6 patients undergoing open-heart surgery. The clip-on device monitored blood parameters in real-time as blood circulated through the cardiopulmonary bypass system, achieving impressive concordance with conventional laboratory testing methods. Notably, the study also validated a new indicator for identifying oxygen deficiencies, showing 92.3% accuracy – a critical capability for preventing hypoxia during surgical procedures. This clinical validation at one of the world's premier medical institutions represents a significant de-risking event for the company's core technology. As Dagi Ben-Noon, CEO of Inspira, noted, 'Achieving 96% accuracy as reflected in our clinical results in real-time blood monitoring without the need for blood draws represents a significant technological breakthrough.' Expanding Technology Ecosystem Shows Commercial Progress The successful HYLA clinical results come amid accelerating commercial momentum for Inspira's broader product ecosystem. The company's INSPIRA ART100 system, which received FDA 510(k) clearance in May 2024 for cardiopulmonary bypass procedures, is now being deployed at leading U.S. hospitals through distribution partner Glo-Med Networks. The system was recently enhanced with new support features designed to assist medical teams, reduce staff overhead, and improve efficiency during critical procedures. Additionally, in February 2025, Inspira reported positive initial results from its collaboration with Ennocure MedTech Ltd. to develop a novel bio-electronic treatment for preventing bloodstream infections. Ex-vivo testing demonstrated a 95% reduction in bacterial presence within 4 hours, showing promise for addressing the estimated 250,000 bloodstream infections related to intravenous lines occurring worldwide annually. Inspira's Strategy Targets Multiple High-Value Markets The successful clinical validation of the HYLA blood sensor represents a crucial step in Inspira's strategy to penetrate multiple high-value medical technology markets. As a standalone technology, HYLA targets the blood gas analyzer market, which the company projects will reach $5.7 billion by 2030 (up from previous estimates of $2.5 billion). When integrated with Inspira's respiratory support systems, the technology strengthens the company's position in the $19 billion mechanical ventilation market. Inspira's approach of combining AI-enhanced monitoring capabilities with innovative respiratory support solutions addresses a critical unmet need in healthcare. With approximately 20 million patients annually requiring mechanical ventilation globally and mortality rates exceeding 50% under current protocols, Inspira's technology ecosystem offers a potential paradigm shift in critical care management by enabling conscious patient treatment with continuous monitoring. * Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by PESG Research, a brand affiliated with the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by Inspira prior to publication. Please review the full disclaimers and compensation disclosures here: SOURCE: PESG Research Copyright Business Wire 2025. PUB: 03/05/2025 08:46 AM/DISC: 03/05/2025 08:47 AM
